C4 Therapeutics

C4 Therapeutics is a company listed under the stock ticker CCCC (US).

View the org chart displaying its 20 main executives

Most searched biographies at C4 Therapeutics

• Andrew Hirsch, Chief Executive Officer and Director
• Donna Grogan, Director
• Utpal Koppikar, Director

Popular executive movements at C4 Therapeutics

• Owen Hughes has joined the company as Director  (posted on November 21 2023).
• Kendra Adams, who was Senior Vice President, Communications and Investor Relations, is promoted to Chief Financial Officer  (posted on September 6 2023).
• Mary Christian has joined the company as Senior Vice President, Regulatory  (posted on August 9 2023).

Create your alert
to follow the executive moves at C4 Therapeutics.

C4 Therapeutics has 2,287 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Delphia Therapeutics has just announced a $67 Million fundraising (posted on May 7 2024).
• Karius has just announced a $100 Million fundraising (posted on May 3 2024).
• Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion
• Vik Bajaj - Director at Interline Therapeutics

Learn more about the Biotechnology industry >

Press releases by C4 Therapeutics

• C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights – C4 Therapeutics
• C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors – C4 Therapeutics
• C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors – C4 Therapeutics
• C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights – C4 Therapeutics
• C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader – C4 Therapeutics
• C4 Therapeutics Appoints Utpal Koppikar to Board of Directors – C4 Therapeutics
• C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma – C4 Therapeutics
• C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022  – C4 Therapeutics
• C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights – C4 Therapeutics
• C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio – C4 Therapeutics
• View more press releases Close

Social media about C4 Therapeutics

• C4 Therapeutics on Wikipedia, Google News & Yahoo Finance
• C4 Therapeutics on LinkedIn, Twitter & YouTube

Contact by email its executives including Glenn Dubin

Call C4 Therapeutics at +1 781...

View the org chart

Register to receive your alert

Report an error